Riverview Trust Company’s 10x Genomics TXG Stock Holding History

Riverview Trust Company’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,764	Closed	-$15.4K	–	560
2025 Q1	$15.4K	Buy	+1,764	New	+$22.2K	0.02%	529
2022 Q3	–	Sell	-290	Closed	-$13K	–	892
2022 Q2	$13K	Buy	+290	New	+$15K	0.01%	595

Other funds holding TXG

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Riverview Trust Company's TXG Position: Q2 2025 in Review

Riverview Trust Company sold out of 10x Genomics (TXG) in Q2 2025, closing a stake of 1,764 shares — an estimated $15.4K sold.

Riverview Trust Company first reported a position in TXG in Q2 2022 and held it in 2 quarters. The position peaked at $15.4K in Q1 2025. 297 funds tracked by Wall St. Rank hold TXG as of Q2 2025.

Riverview Trust Company reported no remaining 10x Genomics position as of Q2 2025 after selling out during the quarter.
Riverview Trust Company sold 1,764 10x Genomics shares in Q2 2025, an estimated $15.4K.
Riverview Trust Company first reported a position in 10x Genomics in Q2 2022 and held it in 2 quarters.
Riverview Trust Company's 10x Genomics position peaked at $15.4K in Q1 2025.
297 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2025.

Based on Riverview Trust Company's 13F filing for Q2 2025, filed 21 Jul 2025.